Sugi Predict

Sugi Predict / Compounds / SCHEMBL344121

SCHEMBL344121

SCHEMBL344121

CC(C)(C)OC(=O)N1CC(=CC#N)C1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ GRM5 P41594 1/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.37
▸ NR1H2 P55055 4/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2558056 0.88 ESR2 (0.46) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL30803371 0.88 ESR2 (0.46) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL14954612 0.88 ESR2 (0.46) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL21044819 0.85 MEN1 (0.42) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL19331872 0.85 MEN1 (0.42) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL19331833 0.85 MEN1 (0.42) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL99227 0.84 GRM5 (0.53) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL25081013 0.82 USP2 (0.52) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL30759041 0.82 USP2 (0.52) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL22730933 0.81 NR1H2 (0.49) USP2SMN1; SMN2CTSKMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 — — US claimed
EP-4157831-B1 PROCESSES OF PREPARING A JAK1 INHIBITOR INCYTE CORP (US) 2024-10-30 — — EP claimed
US-11685731-B2 Processes of preparing a JAK1 inhibitor INCYTE CORPORATION (US) 2023-06-27 — — US claimed
EP-4157831-A1 PROCESSES OF PREPARING A JAK1 INHIBITOR Incyte Corporation (US) 2023-04-05 — — EP claimed
CN-115836065-A Methods of making JAK1 inhibitors 因赛特公司 2023-03-21 — — CN claimed
US-20190100538-A1 PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2019-04-04 — — US claimed
WO-2016125080-A2 PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2016-08-11 — — WO claimed
US-20250368666-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES INC (US) 2025-12-04 — — US disclosed
WO-2025245351-A1 SUBSTITUTED ARYL SULFONAMIDES AND COMPOSITIONS AND USES THEREOF XENON PHARMACEUTICALS INC. (CA) 2025-11-27 — — WO disclosed
US-12428426-B2 Process and intermediates for preparing a JAK1 inhibitor INCYTE CORPORATION (US) 2025-09-30 — — US disclosed
EP-4620528-A2 BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS Incyte Holdings Corporation (US) 2025-09-24 — — EP disclosed
EP-4275756-B1 BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS INCYTE HOLDINGS CORP (US) 2025-09-03 — — EP disclosed
US-12404275-B2 Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof PRIMEGENE (BEIJING) CO., LTD. (CN) 2025-09-02 — — US disclosed
WO-2010039939-A1 JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES INCYTE CORPORATION (US) 2010-04-08 — — WO disclosed
US-20090318405-A1 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-12-24 — — US disclosed
WO-2009114512-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — WO disclosed
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — US disclosed
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — US disclosed
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — US disclosed
WO-2009064835-A1 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318405-A1 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS JAK1, JAK2, JAK3 USP2 2039/4885SMN1; SMN2 3345/4885CTSK 2102/4885
US-20250368666-A1 INDAZOLE COMPOUNDS FGFR1, FGFR3, FGFR2 USP2 3629/4885SMN1; SMN2 2326/4885CTSK 1423/4885
US-12428426-B2 Process and intermediates for preparing a JAK1 inhibitor JAK1, JAK2, JAK3 USP2 2339/4885SMN1; SMN2 4476/4885CTSK 3469/4885
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 USP2 720/4885SMN1; SMN2 3910/4885CTSK 2799/4885
US-20190100538-A1 PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF JAK1, JAK2, JAK3 USP2 3472/4885SMN1; SMN2 4197/4885CTSK 2486/4885
US-11685731-B2 Processes of preparing a JAK1 inhibitor JAK1, JAK2, JAK3 USP2 1861/4885SMN1; SMN2 3992/4885CTSK 3786/4885
US-12404275-B2 Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof JAK2, TYK2, JAK1 USP2 4517/4885SMN1; SMN2 2253/4885CTSK 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.